The purpose of this study is to determine whether erlotinib will be effective in controlling
cancer that has returned after treatment with radiation. This study will also determine what
effects, good and/or bad, this drug has.
1. Pathologically confirmed diagnosis of recurrent or second primary squamous cell
2. Recurrence or second primary of the oral cavity, oropharynx, hypopharynx, or larynx.
Recurrent neck metastasis with unknown primary is allowed
3. Prior radiation therapy for head and neck cancer
4. Disease must be considered surgically resectable or candidate for curative
5. Adequate diagnostic workup
6. Zubrod Performance Status 0-2
7. Life expectancy 12 weeks
8. Age 19, 9. Adequate laboratory data.
1. Prior invasive cancers other than head and neck cancer unless disease free for a
minimum of 3 years. (Prior non-melanomatous skin cancer and previous carcinoma in
situ are permissible)
2. Patients who are pregnant or lactating
3. Psychological condition that renders the patient unable to understand the informed
4. Any situation or condition that will interfere with adherence to study activities.